Xuanzhu, a Novel Drug Subsidiary of Sihuan Pharm, Completes $96 Million Round
publication date: Jan 3, 2022
Xuanzhu Biopharm, a subsidiary of Sihuan Pharm, completed a $96 million Series B financing to develop novel drugs for China. The financing follows an even larger $152 million Series A that closed in 2020. Nearly ten years old, Xuanzhu has built a 400 member team led by oversea returnee scientists. It has independent R&D capabilities that are not dependent on in-licensings or CROs. The company, which develops small molecule and biologic drugs, has developed a portfolio of more than 25 candidates, including two NDA stage products. The B round was led by Sunshine Life Insurance Company. More details....
Stock Symbol: (HK: 0460)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.